Strategies to reduce mortality and morbidity due to AIDS-related cryptococcal meningitis in Latin America

Braz J Infect Dis. 2013 May-Jun;17(3):353-62. doi: 10.1016/j.bjid.2012.10.020. Epub 2013 May 10.

Abstract

Latin America is the region with the third most AIDS-related cryptococcal meningitis infections globally. Highly active antiretroviral therapy (HAART) has reduced the number of infections; however, the number of deaths and the case-fatality rate continues to be unacceptable. In this review, we focus on the burden of AIDS-related cryptococcosis in Latin America and discuss potential strategies to reduce early mortality from Cryptococcus. In this review, we highlight the importance of: (1) earlier HIV diagnosis and HAART initiation with retention-in-care to avoid AIDS; (2) pre-HAART cryptococcal antigen (CRAG) screening with preemptive fluconazole treatment; (3) better diagnostics (e.g. CRAG testing); and (4) optimal treatment with aggressive management of intracranial pressure and induction therapy with antifungal combination. Implementation of these strategies can reduce cryptococcal-related deaths, improve care, and reduce healthcare costs.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • AIDS-Related Opportunistic Infections / drug therapy
  • AIDS-Related Opportunistic Infections / mortality*
  • Antifungal Agents / therapeutic use
  • Antiretroviral Therapy, Highly Active*
  • Humans
  • Latin America / epidemiology
  • Meningitis, Cryptococcal / drug therapy
  • Meningitis, Cryptococcal / mortality*

Substances

  • Antifungal Agents